Almirall and Quintiles have reached a partnership agreement to promote Almirall’s respiratory portfolio in the UK commencing with a new, long-acting antimuscarinic (LAMA) delivered via an innovative, multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD). The treatment was approved by the European Commission in July as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. “We are proud to bring the first product in a truly innovati...